Insider Selling: Tempus AI (NASDAQ:TEM) COO Sells $461,600.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $92.32, for a total value of $461,600.00. Following the sale, the chief operating officer directly owned 130,000 shares in the company, valued at $12,001,600. This trade represents a 3.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, August 19th, Ryan Fukushima sold 17,460 shares of Tempus AI stock. The stock was sold at an average price of $74.65, for a total value of $1,303,389.00.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $96.39 on Friday. The business’s 50 day simple moving average is $78.89 and its 200-day simple moving average is $64.70. The firm has a market capitalization of $16.75 billion, a price-to-earnings ratio of -81.00 and a beta of 4.87. The company has a debt-to-equity ratio of 2.58, a current ratio of 1.54 and a quick ratio of 1.43. Tempus AI, Inc. has a 12 month low of $31.36 and a 12 month high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Friday, August 8th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The business had revenue of $314.64 million during the quarter, compared to analysts’ expectations of $296.84 million. During the same period last year, the company posted ($6.86) EPS. The company’s revenue was up 89.5% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC purchased a new position in Tempus AI in the third quarter valued at approximately $28,000. Concord Wealth Partners raised its holdings in Tempus AI by 308.0% in the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after buying an additional 308 shares during the period. Allworth Financial LP raised its holdings in Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after buying an additional 450 shares during the period. SouthState Corp raised its holdings in Tempus AI by 3,761.5% in the second quarter. SouthState Corp now owns 502 shares of the company’s stock valued at $32,000 after buying an additional 489 shares during the period. Finally, Cherry Tree Wealth Management LLC purchased a new position in Tempus AI in the first quarter valued at approximately $31,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on TEM shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a report on Wednesday. Piper Sandler reissued a “neutral” rating on shares of Tempus AI in a report on Friday, August 8th. Bank of America upped their price objective on shares of Tempus AI from $68.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, June 25th. BTIG Research upped their price objective on shares of Tempus AI from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, August 20th. Finally, Guggenheim upped their price objective on shares of Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, September 26th. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $71.83.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.